| 产品描述: | 普罗塔克;PROTAC;GMB-475 是一种靶向蛋白水解的嵌合体(PROTAC),它以变构方式靶向 BCR-ABL1 蛋白并募集 the E3 ligase Von Hippel-Lindau (VHL),从而导致泛素化并随后降解致癌融合蛋白 ;InformationGMB-475 is a proteolysis-targeting chimera (PROTAC) that allosterically targets BCR-ABL1 protein and recruit the E3 ligase Von Hippel-Lindau (VHL), resulting in ubiquitination and subsequent degradation of the oncogenic fusion protein.TargetsBCR-ABL1 ; E3 ligaseIn vitroGMB-475 induces rapid proteasomal degradation and inhibition of downstream biomarkers, such as STAT5 in both human CML K562 cells and murine Ba/F3 cells expressing BCR-ABL1. GMB-475 inhibits the proliferation of certain clinically relevant BCR-ABL1 kinase domain point mutants and further sensitizes Ba/F3 BCR-ABL1 cells to inhibition by imatinib, while demonstrating no toxicity toward Ba/F3 parental cells.Cell Research(from reference)Cell lines:K562 cell line, Ba/F3 murine cell lines (Ba/F3 BCR-ABL1 cells, Ba/F3 parental cells) Concentrations:0.001-0.300 μM, 5 μM Incubation Time:3 days, 8 h |
| 体内研究: |
GMB-475 (5 mg/kg; 每 2 天 1 次; 10 天; 腹腔注射) 通过靶向降解 BCR-ABL1b 并联合达沙替尼 可用于改善小鼠 BCR::ABL1 突变体的慢性粒细胞白血病。 |
| 参考文献: |
1. Burslem GM, et al. Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation. Cancer Res. 2019 Sep 15;79(18):4744-4753. 2. Ye W, et al. The proteolysis targeting chimera GMB-475 combined with dasatinib for the treatment of chronic myeloid leukemia with BCR::ABL1 mutants. Front Pharmacol. 2022 Oct 3;13:931772. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
1.16 ml |
5.801 ml |
11.602 ml |
| 5 mM |
0.232 ml |
1.16 ml |
2.32 ml |
| 10 mM |
0.116 ml |
0.58 ml |
1.16 ml |
| 50 mM |
0.023 ml |
0.116 ml |
0.232 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |